Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Melanoma-intrinsic β-catenin Signalling Prevents Anti-tumour Immunity

Stefani Spranger, R. Bao, T. Gajewski
Published 2015 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3, 4, 5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8+ T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.
This paper references
10.1038/76957
CCR5 provides a signal for microbial induced production of IL-12 by CD8α+ dendritic cells
J. Aliberti (2000)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1038/nature11538
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
J. Landsberg (2012)
10.1038/nature10755
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting
H. Matsushita (2012)
10.1158/0008-5472.CAN-11-3218
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
Gulsun Erdag (2012)
10.4049/jimmunol.1000060
Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075
Stefani Spranger (2010)
10.1158/0008-5472.CAN-12-1187
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.
W. Peng (2012)
10.4049/jimmunol.1102282
Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells
T. Yaguchi (2012)
10.1038/ng.356
BRafV600E cooperates with Pten silencing to elicit metastatic melanoma
D. Dankort (2009)
10.1186/1471-2105-12-323
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li (2011)
10.4049/jimmunol.1001562
β-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells–Phospholipase C-γ1 Phosphorylation
Gregory Driessens (2011)
10.1093/nar/gkq603
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
K. Wang (2010)
10.1126/scitranslmed.3006504
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger (2013)
An integrated map of genetic variation from 1,092 human genomes
M. V. García (2012)
10.1038/jid.2013.515
Flt3L-dependence helps define an uncharacterized subset of murine cutaneous dendritic cells
Shamim A. Mollah (2014)
10.1038/ni.1724
Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells
S. Bedoui (2009)
Pten 2/2 /CAT-STA mice. a, Distribution of T-cell subsets in Braf V600E /Pten 2/2 and Braf V600E /Pten 2/2 /CAT-STA tumours
Braf
10.1016/j.ccr.2011.10.030
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
W. Damsky (2011)
10.1038/nature10673
Cancer immunotherapy comes of age
I. Mellman (2011)
10.1093/nar/gkn760
STRING 8—a global view on proteins and their functional interactions in 630 organisms
L. Jensen (2009)
10.1007/s00262-011-1172-6
An immune-active tumor microenvironment favors clinical response to ipilimumab
R. Ji (2011)
10.1016/J.MOLIMM.2006.08.006
Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages.
Ciera Khuu (2007)
10.1158/0008-5472.CAN-11-1620
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo (2012)
10.1056/NEJMoa1302369
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
10.1002/DVG.20205
Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice
M. Bosenberg (2006)
10.1200/JCO.2013.53.0105
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
10.1186/2051-1426-2-3
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
Stefani Spranger (2014)
10.1038/sj.onc.1205562
Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia
F. Gounari (2002)
10.1126/science.1164206
Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity
K. Hildner (2008)
Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
T. C. Manning (1997)
10.1101/GAD.1190304
Hedgehog signaling in the neural crest cells regulates the patterning and growth of facial primordia.
Juhee Jeong (2004)
10.1016/S0002-9440(10)65278-9
Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma.
D. Rimm (1999)
10.1084/jem.20092140
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens
Sarah L. Jongbloed (2010)
naive (CD62L 1 CD44 2 ) and effector (CD62L 2 CD44 1 ) T cells (pre-gated on CD3 1 CD8 1 T cells), and one representative example of CD44/CD45RA staining (c)
Extended Data Figure 4 | Characterization of the T-cell infiltrate in
10.1007/s00262-011-1026-2
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
A. Cipponi (2011)
10.1038/nrclinonc.2013.153
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
H. L. Kaufman (2013)
10.1084/jem.20101159
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
M. Fuertes (2011)
10.1158/0008-5472.CAN-08-2281
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
H. Harlin (2009)
10.1158/0008-5472.CAN-08-2634
Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer.
A. Cheung (2008)
10.1074/jbc.M111.247825
N-myc Downstream-regulated Gene 2, a Novel Estrogen-targeted Gene, Is Involved in the Regulation of Na+/K+-ATPase*
Y. Li (2011)
10.1126/science.1129139
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
J. Galon (2006)
10.1101/GAD.1516407
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
D. Dankort (2007)
10.1038/nprot.2008.73
Analyzing real-time PCR data by the comparative CT method
Thomas D. Schmittgen (2008)
Quantification and comparison of PD-1/Lag3 double-positive T cells in Braf V600E /Pten 2/2 and Braf V600E /Pten 2/2 /CAT-STA tumours
10.1016/S0960-9822(07)00488-5
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice
A. Suzuki (1998)
10.1093/bioinformatics/btq170
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
M. Wilkerson (2010)



This paper is referenced by
10.18632/oncotarget.6600
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
Ilaria Penna (2016)
10.3390/ijms18102229
Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications
Jessica Roelands (2017)
10.5772/INTECHOPEN.79273
Dendritic Cells: The Tools for Cancer Treatment
Hanne Locy (2018)
10.1254/fpj.148.144
Current condition and issues of animal evaluation models for cancer immunotherapy.
Motoya Mie (2016)
10.13105/wjma.v7.i3.101
PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives
Jian Li (2019)
10.1158/2326-6066.CIR-18-0595
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
S. Palakurthi (2019)
10.30564/jor.v1i2.1409
Signaling Pathways Associated with Cancer Stem Cells Play a Significant Role in Immunotherapy Resistance
Y. Zhu (2019)
10.1158/2326-6066.CIR-17-0712
Wnt3a/β-Catenin Signaling Conditions Differentiation of Partially Exhausted T-effector Cells in Human Cancers
V. Schinzari (2018)
10.1634/theoncologist.2017-0354
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Y. Chae (2018)
10.20517/cdr.2020.11
A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
Y. Fujiwara (2020)
10.2147/OTT.S159979
β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion
S. Liu (2018)
Regulation of the Inflamed Tumor Phenotype in Melanoma Immunotherapy
Jennifer A. Lo (2016)
10.1016/j.imlet.2019.06.008
Major fundamental factors hindering immune system in defense against tumor cells; the link between insufficiency of innate immune responses, metabolism, and neurotransmitters with effector immune cells disability.
Saman Bahrambeigi (2019)
10.1038/nrc.2017.117
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger (2018)
10.1016/J.CIMID.2018.12.006
Obstacles to T cell migration in the tumor microenvironment.
Alba Nicolás-Boluda (2019)
10.1016/j.immuni.2016.02.025
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
B. Mlecnik (2016)
10.1101/546069
Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis
Jessica Roelands (2019)
10.1038/s41598-019-41182-5
The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro
Dmitry Stakheev (2019)
10.1016/j.trecan.2019.10.006
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga.
Irene Catalano (2019)
10.1038/mto.2016.34
Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy
Marcin Komorowski (2016)
10.1016/j.it.2016.09.003
Antigen Presentation in Transplantation.
M. Alegre (2016)
10.1158/1535-7163.MCT-16-0309
Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
S. Ganesh (2016)
10.1172/JCI95351
β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
J. Nsengimana (2018)
10.1080/2162402X.2015.1052212
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
B. Homet Moreno (2016)
10.1038/onc.2017.207
Wnt/β-catenin activation and macrophage induction during liver cancer development following steatosis
A. Debebe (2017)
10.1158/1078-0432.CCR-15-2665
CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
Y. Lee (2016)
10.3389/fimmu.2020.578877
Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
Yangzhi Qi (2020)
10.1016/j.ccell.2020.03.017
Acquired Resistance to Immune Checkpoint Inhibitors.
A. Schoenfeld (2020)
10.1007/s40265-020-01270-7
Mechanisms of Resistance to PD-1 Checkpoint Blockade
Justin C. Moser (2020)
10.1126/science.aaf0683
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
A. Kamphorst (2017)
10.1136/esmoopen-2019-000631
Tailoring precision immunotherapy: coming to a clinic soon?
S. Han (2020)
Implication des cellules myéloïdes immunosuppressives (MDSC) et des lymphocytes TH17 dans l’efficacité des chimiothérapies et de l’immunothérapie
E. Limagne (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar